基石药业-B(02616)今日盘中大涨6.73%，引起了市场的广泛关注。
消息面上，公司上月底公布，其核心产品CS2009单药针对肺癌的I/II期初步疗效数据表现积极。公司计划于2026年底前启动CS2009的首批III期全球多中心临床试验，重点布局非小细胞肺癌、结直肠癌、小细胞肺癌等适应症，这为未来的产品上市和商业化前景注入了强心剂。
此外，招商证券国际发布最新研报，大幅上调基石药业目标价131.5%至16.9港元，并维持“增持”评级。该行提高了对CS2009的资产估值，认为公司管理层研发思路明确、战略清晰，并存在与海外大型药企开展深度合作的可能性，看好CS2009这款三特异性抗体药物的市场潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.